Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory, offering panel and single gene genetic tests as well as exome analysis.
Invitae's assay for panel and single gene tests includes both full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Download our High-quality genetic testing, simplified flyer to learn more about Invitae's commitment to delivering high-quality, affordable testing.
Invitae has incorporated supplemental RNA testing into the variant classification process for variants of uncertain significance (VUS). We will be analyzing VUS that are predicted to affect splicing and have been identified in a gene from any of our hereditary cancer panels.
An amended report may be issued if the supplemental RNA data contributes to a reclassification of a VUS in your patient’s report.
As always, Invitae is dedicated to utilizing the very latest variant interpretation techniques to better understand the clinical impact of each variant identified by our genetic tests.
Invitae's boosted exome analysis utilizes advanced next-generation sequencing (NGS) capture technology with boosted coverage of medically relevant genes. Customized capture baits enhance the coverage of hard-to-sequence areas of the exome and allow detection of intragenic copy number variants.
To learn more about Invitae's exome analysis, please refer to the Technical description section of the Exome page.